BRE 17107: A Phase Ib/II Trial of Atezolizumab (an Anti-PD-L1 Monoclonal Antibody) With Cobimetinib (a MEK1/2 Inhibitor) or Idasanutlin (an MDM2 Antagonist) in Metastatic ER+ Breast Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Atezolizumab (Primary) ; Cobimetinib (Primary) ; Idasanutlin (Primary)
- Indications Advanced breast cancer; Carcinoma
- Focus Adverse reactions; Therapeutic Use
- 01 Dec 2019 Status changed from recruiting to active, no longer recruiting.
- 27 Jun 2019 Planned number of patients changed from 92 to 80.
- 02 Jul 2018 New trial record